Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650

Benzinga Newsdesk www.benzinga.com Negative 93.8%

Neg 93.8% Neu 0% Pos 0%

Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $750 to $650.